Introduction
The c-Jun proto-oncogene is the prototypical member of the AP-1 transcription factor family. This family of proteins contains distinct modular domains involved in transactivation, dimerization and DNA binding. The cJun protein forms dimers with members of the Jun (cJun, Jun B, Jun D), Fos (c-Fos, Fra 1, Fra 2, Fos B), ATF/CREB (ATF2, ATF3), and Maf/Nr1 families through a common leucine zipper motif (Chinenov and Kerppola, 2001; Shaulian and Karin, 2001; van Dam and Castellazzi, 2001; Vogt, 2001 ). This prerequisite dimerization affects DNA binding affinity and site recognition as well as transactivation potential (Chinenov and Kerppola, 2001; Shaulian and Karin, 2001; van Dam and Castellazzi, 2001; Vogt, 2001) . In the direct model of AP-1 regulated gene expression, AP-1 dimeric complexes recognize and bind the consensus sequence TGAC/GTCA in the promoters and enhancers of target genes. However, AP-1 is fairly promiscuous and recognizes numerous non-canonical variations of this site as well as variations of the eight base pair consensus binding site for the ATF/CREB proteins, TGACGTCA (Benbrook and Jones, 1990; Hadman et al., 1993; Ryseck and Bravo, 1991) . Numerous reports have demonstrated dramatic differences in DNA binding and transcriptional activation by specific dimers within the AP-1 superfamily. In general, Jun/Fos heterodimers are more stable than c-Jun/c-Jun homodimers and bind more efficiently to the AP-1 consensus DNA element. Specific heterodimeric combinations also exhibit unique specificities. For instance, c-Jun/ATF2 will recognize and bind to the AP-1 site in the urokinase plasminogen activator promoter with the sequence TGAAGTCA with high affinity (de Cesare et al., 1995) . c-Jun/c-Fos does not bind well to this sequence and c-Jun homodimers do not bind at all (de Cesare et al., 1995) . Similarly, the AP-1 like site in the proenkephalin enhancer, TGCGTCA, binds well to Jun D but not to Jun B homodimers (Kobierski et al., 1991) . We have demonstrated similar qualitative sequence specificity differences for variations of AP-1 and CREB target sequences between v-Jun and c-Jun isolated from chicken embryo fibroblasts (Hadman et al., 1993) . The existence of both high and low affinity AP-1 binding sites has important gene regulatory implications.
Specifically, target gene regulation by AP-1 proteins will depend not only on binding site context but also on the levels of specific AP-1 dimers expressed at any given time. In addition to these direct mechanisms of transcriptional control, Jun family proteins can also influence gene regulation through indirect mechanisms, by interacting with a variety of different proteins (Bengal et al., 1992; Nishitani et al., 1999; Schu¨le et al., 1990; Stein et al., 1993a,b; Touray et al., 1991; Ubeda et al., 1999; Yang-Yen et al., 1990 . For example, c-Jun can interact with the SP-1 transcription factor to regulate expression of p21WAF1 and 12(S)-lipoxygenase, independent of binding to an AP-1 DNA element (Chen and Chang, 2000; Kardassis et al., 1999) . Thus, gene regulation by AP-1 can be both direct and indirect. Taken together, these studies demonstrate the capability for unique gene target regulation based on the compositional properties of AP-1 dimers. It is these gene regulatory patterns, which ultimately influence the biological phenotype.
A number of studies have demonstrated that c-Jun and other AP-1 proteins play an important role in breast cancer. Not only do many breast tumors express high levels of c-Jun (Horne et al., 1996; MildeLangosch et al., 2000; Tiniakos et al., 1994) but this expression correlates with the development of distant metastases especially to bone (Gee et al., 2000) . There is also a trend towards failure to respond to tamoxifen therapy and shorter survival in patients with c-Jun positive breast tumors (Gee et al., 2000) . This increased AP-1 activity in tamoxifen resistant ER positive primary breast tumors suggests an agonistic response between tamoxifen bound estrogen receptor and AP-1 proteins. In addition to c-Jun, other AP-1 proteins have also been implicated in breast cancer development. Expression of the c-Fos proto-oncogene is significantly correlated with failure to respond to endocrine therapy and poor survival (Gee et al., 1995) . Fra-1 expression correlates with estrogen receptor negative breast tumors (Bamberger et al., 1999) and interestingly is a target of c-Jun (Bergers et al., 1995; Rinehart-Kim et al., 2000) . In contrast, FosB expression has been demonstrated to correlate with well differentiated estrogen receptor positive tumors (Bamberger et al., 1999) . These results suggest that FosB and Fra1 exhibit differential involvement in breast tumor pathogenesis (Bamberger et al., 1999) . Finally, comparison of gene expression patterns from 13 different breast cancer cell lines has revealed dramatically elevated expression of both c-Jun and Fra-1 in the highly invasive lines (Zajchowski et al., 2001) . We have found that overexpression of c-Jun in the MCF7 cell line induces a number of changes in gene expression (Rinehart-Kim et al., 2000) . Of particular interest, is an increase in the expression of Fra-1 (Rinehart- Kim et al., 2000) . Significantly, these c-Jun/MCF7 cells also exhibit dramatic phenotypic changes characteristic of malignant progression, including increases in cell migration and invasion (Smith et al., 1999) . Taken together, these studies demonstrate that the c-Jun/MCF7 cell culture model provides a useful tool in which to study mechanisms involved in breast cancer development and progression.
One of the primary gene targets upregulated by cJun in MCF7 breast cancer cells is a product called SPARC (Rinehart-Kim et al., 2000) . The SPARC (secreted protein acidic and rich in cysteine) gene product, also known as osteonectin and BM-40, has come into focus recently because of its role as an antiadhesion matricellular protein that mediates interactions between the extracellular matrix (ECM) and cells (Bradshaw and Sage, 2001; Brekken and Sage, 2001; Greenwood and Murphy-Ullrich, 1998; Motamed, 1999; Reed and Sage, 1996; Rosenblatt et al., 1997; Yan and Sage, 1999) . It is involved in a variety of diverse biological processes including tissue remodeling, cell adhesion, proliferation, differentiation, matrix synthesis/turnover, angiogenesis and tumor cell migration and invasion (Bradshaw and Sage, 2001; Motamed, 1999; Reed and Sage, 1996; Yamanaka et al., 2001; Yan and Sage, 1999) . Because of its diverse biological activities, aberrant SPARC expression has been found associated with a variety of pathologic processes. Some, including melanoma, meningioma and metastatic carcinomas of breast, prostate and colon, are associated with increased SPARC expression (Bellahcene and Castronovo, 1995; Graham et al., 1997; Jacob et al., 1999; Kato et al., 2000; Ledda et al., 1997a; Porte et al., 1995 Porte et al., , 1998 Porter et al., 1995; Sturm et al., 2002; Thomas et al., 2000) . Importantly, not only is SPARC expression correlated with tumor metastasis but its targeted downregulation is sufficient to reverse the invasive behavior of malignant melanoma cells (Ledda et al., 1997b) . Interestingly, increased SPARC expression has been observed in conjunction with increased c-Jun and Fra-1 expression in a panel of invasive breast cancer cell lines (Zajchowski et al., 2001) . Taken together, these studies strongly suggest that SPARC is an important mediator of tumor cell progression.
The objective of this study was to examine the role played by SPARC in mediating the invasive phenotypic behaviors induced by c-Jun and to determine, mechanistically, how c-Jun modulates SPARC expression.
Results

SPARC RNA and protein are elevated in c-Jun overexpressing MCF7 cells
In Figure 1a we show that SPARC expression is undetectable in MCF7 cells using a sensitive RT -PCR assay. As before, SPARC RNA is highly expressed in c-Jun overexpressing MCF7 cells (c-Jun/MCF7). In Figure 1b , we demonstrate by Western blot analysis the expression of a 43 kDa glycosylated form of SPARC in c-Jun/MCF7 cells that is absent in the parental MCF7 cells. These results demonstrate up-regulation of SPARC RNA and protein in response to overexpression of c-Jun. Cumulatively, such dramatic upregulation of SPARC suggests an 'on/off' mechanism of SPARC regulation in response to c-Jun in MCF7 breast cancer cells. Our model therefore represents both transcriptionally 'active' (c-Jun/MCF7) and 'inactive' (MCF7 parental) states of SPARC gene transcription which provides a novel system in which to examine the mechanisms of regulation and the phenotypic effects mediated by SPARC.
Overexpression of SPARC in MCF7 cells is not sufficient to promote cell migration and invasion
Having identified SPARC as a gene highly upregulated in response to c-Jun in MCF7 cells, we next wanted to determine its role in mediating cell migration and invasion. To accomplish this, we generated a series of stable SPARC overexpressing MCF7 cell lines using retroviral mediated gene transfer. Several stable cell clones were selected that overexpress SPARC protein (Figure 2a) . Although the level of expression of SPARC in each of the three MCF7/SPARC cell lines varied (Figure 2a) , at least one of the MCF7/SPARC cell lines (MCF7/SPARC-1) expresses SPARC at a level similar to that seen in the c-Jun/MCF7 cell lines. These clones were subsequently assayed for motility and invasion. In comparison to parental MCF7 cells, none of the SPARC/MCF7 cell lines showed a significant change in motility through gelatin coated membranes (Figure 2b ) or invasion through collagen IV and Matrigel coated membranes (Figure 2c ). These results demonstrate that SPARC overexpression alone is not sufficient to induce migration and invasion in MCF7 cells and suggest that other cellular changes induced by c-Jun are required for these phenotypic changes.
Antisense suppression of SPARC in c-Jun/MCF7 cells prevents migration and invasion
In order to determine if SPARC is necessary or involved in migration and invasion by c-Jun/MCF7 cells we developed a means for its specific suppression. A previous study examining the role of SPARC in human melanoma cells showed that anti-sense inhibition of SPARC expression diminished adhesion and invasion and abrogated in vivo tumor formation in mice (Ledda et al., 1997b) . Therefore, we chose to use this strategy to suppress SPARC expression in our c-Jun/MCF7 cells. To accomplish this, we constructed replication incompetent adenovirus expressing SPARC in the anti-sense orientation as well as a control adenovirus expressing the Infection of c-Jun/MCF7 cells with adenovirus-b-gal was used to determine an optimal multiplicity of infection (MOI) in which most cells became infected without showing cytotoxic effects. This MOI was subsequently used to infect c-Jun/MCF7 cells with the adenovirus-SPARC-antisense virus. We analysed SPARC protein expression at various time points postinfection to determine the point at which SPARC expression was suppressed to the greatest extent ( Figure  3a) . Figure 3b shows a marked inhibition in SPARC protein expression 24 h following adenovirus-SPARCanti-sense infection (MOI 5) in c-Jun/MCF7 cells. This time point and MOI was subsequently used to assess motility and invasion in response to infection with SPARC anti-sense or b-gal control virus. Interestingly, c-Jun/MCF7 cells infected with SPARC anti-sense virus are significantly less motile than cells infected with the same MOI of control virus (Figure 3c ). Additionally, cJun/MCF7 cells infected with the SPARC anti-sense virus had a significantly diminished invasive capacity when compared to control infected cells (Figure 3d ). Taken together, these results are consistent with a mechanism by which SPARC upregulation in response to c-Jun is a pivotal event leading to the induction of motility and invasion in c-Jun/MCF7 cells.
Analysis of SPARC promoter activation in MCF7, c-Jun/ MCF7 and JunD/MCF7 cell lines
Having identified SPARC as a phenotypically relevant target of c-Jun we were interested in determining the mechanism by which SPARC promoter activity is regulated. In order to examine the mechanism by which c-Jun stimulates SPARC expression, we examined SPARC promoter activity using a human SPARC promoter-luciferase reporter. The large SPARC promoter fragment encompasses upstream nucleotides from 71409 to +28 relative to the transcriptional start site. Transient transfection with the large SPARC promoter-luciferase vector (71409/+28) into MCF7 cells resulted in very little promoter activity ( Figure  4b ). However, SPARC promoter activity was increased 20 -25-fold in c-Jun/MCF7 cells relative to parental MCF7s (Figure 4b) .
In order to determine if SPARC upregulation is specific to c-Jun we examined the ability of another Jun family protein, JunD, to induce SPARC expression. Northern blot analysis (Figure 4a ) revealed that, as before, the c-Jun/MCF7 cell line expresses high levels of SPARC RNA. In contrast, SPARC expression is undetectable in the JunD/MCF7 and parental MCF7 cell lines. As expected, neither of the JunD/MCF7 cell lines stimulated SPARC promoter activity (Figure 4b) . Interestingly, the phenotype of the JunD/MCF7 cell lines resembles the parental MCF7 cells and does not show any of the phenotypic changes induced by c-Jun (data not shown-manuscript in preparation). These results demonstrate a c-Jun, but not JunD, responsive element is contained within this 1437 base promoter fragment.
DNA binding to a non-canonical AP-1 site located at 71051/71045 in the human SPARC promoter Sequence analysis of the 1437 SPARC promoter fragment revealed the presence of three non-canonical AP-1 sites that differ from the core consensus by a single nucleotide (Figure 5a ). There are no consensus AP-1 binding sites present within this fragment. Oligonucleotide primers of each of these non-canonical AP-1 sites were generated, and assayed, for their ability to bind proteins from nuclear extracts, derived from MCF7, JunD/MCF7 and c-Jun/MCF7 cells. Only one of these sites (71051 to 71045) showed any significant binding activity. Gel mobility shift analysis of this AP-1 'like' site is shown in (Figure 5b ). The MCF7 and JunD/MCF7 nuclear extracts failed to bind this fragment. In contrast, the c-Jun/MCF7 nuclear extracts exhibit a single complex (Figure 5b ). In order to determine the composition of this complex, we performed antibody competition and supershift analysis ( Figure 5b ). An antibody directed against the DNA binding region of c-Jun specifically blocked AP-1 complex formation at this site indicating c-Jun is part of this complex. Because this antibody is directed against the DNA binding domain, the effect seen is a block in binding rather than a supershift (Hadman et al., 1993) . Incubation with anti-Fra-1 antibody resulted in a supershift indicating that this complex is composed largely of c-Jun/Fra-1 dimers. As expected, incubation with a control antibody had no effect on AP-1 binding. Interestingly, we have previously shown dramatic upregulation of Fra-1 in response to c-Jun in these cJun/MCF7 cells potentially making Fra-1 a preferred dimerization partner for c-Jun (Rinehart- Kim et al., 2000) . Next, we wanted to examine the specificity of AP-1 binding to the non-canonical site at 71051/ 71045. We pre-incubated c-Jun/MCF7 nuclear extracts with unlabeled AP-1 consensus oligonucleotide or an unrelated, heterologous competitor. The consensus AP-1 competitor completely abolished AP-1 binding to the probe 71051/71045 at the lowest concentration whereas competition with an unrelated competitor had only a modest effect even at 506 molar excess suggesting that this non-canonical site is capable of binding AP-1, but with low affinity ( Figure  6 ). These results demonstrate specificity of binding by the AP-1 complex consisting of c-Jun/Fra-1 dimers and suggest that c-Jun/Fra-1 recognition of a non-canonical AP-1 site may provide a direct mechanism of SPARC promoter activation in c-Jun/MCF7 cells.
Site directed mutagenesis of the AP-1 element at 71051/ 71045 to a high affinity or low affinity site does not alter SPARC promoter activation in c-Jun/MCF7 cells To determine the functional significance of the non canonical AP-1 site located at 71051/71045 we introduced point mutations to make the site a perfect consensus (TGAGTCA) or a triple mutant (CGAAT-GA). Gel shift analysis with these mutants demonstrated that, as expected, mutation to a high Figure 7a ). If this site is critical for promoter activation mediated by direct AP-1 binding it would be expected that mutation to a high or low affinity site would result in a change in transactivation potential relative to the wildtype sequence. On the other hand, if mutation of this site did not significantly effect promoter activation this would suggest that it is either not required or not active when taken out of the full genomic context. We used overlapping PCR directed mutagenesis to introduce these mutations into the SPARC promoter fragment (71409/+28). Interestingly, transient transfection of the site-directed mutants into c-Jun/MCF7 cells resulted in similar promoter activation suggesting that this AP-1 binding site does not play a critical role in c-Jun mediated stimulation of SPARC promoter activity (Figure 7b) .
Identification of the c-Jun responsive region in the human SPARC promoter
Because the AP-1 site at 71051 does not appear to play an important role in c-Jun mediated SPARC expression, we initiated a deletion analysis in order to pinpoint the c-Jun responsive element. A 5' truncation resulting in a SPARC promoter spanning the region from 7120 to +28 was tested for activity in MCF7, JunD/MCF7 and c-Jun/MCF7 cells. This region (7120/+28) has several interesting features including a GC box (GGCGGG) and 15 repeats of the sequence GGA (Figure 8a ). These GGA sequences exist as single (GGA), di-(GGAGGA) and tri-(GGAGGAGGA) repeat 'modules'. This portion of the SPARC promoter is well conserved among species with the highest degree of homology near the 3' end of the promoter region . Surprisingly, luciferase reporter assays conducted using this region from 7120/+28 resulted in retention of approximately 80 -90% of promoter activity in c-Jun/MCF7 cells relative to the fragment 71409/+28 (Figure 8b ). This suggests that a primary c-Jun responsive region is located within this 148 base pair region.
To further resolve the c-Jun responsive element, we constructed an additional 5' promoter deletion which resulted in a promoter fragment spanning from 770/ +28 relative to the transcriptional start site ( Figure  9a ). Transient transfection of this construct into c-Jun/ MCF7 cells resulted in almost a 90% reduction in promoter activity relative to the 7120/+28 promoter fragment (Figure 9b ). Of note, this deletion resulted in the elimination of several conserved promoter features including 10 GGA repeat sequences as well as the GC box. Taken together, these results suggest that the 50 base pair region between 7120 and 770 is a primary regulatory region responsive to c-Jun. Because this region does not contain any sequence resembling an AP-1 site it is most likely that c-Jun stimulates the SPARC promoter through an indirect mechanism.
Gel shift analyses of the c-Jun responsive region spanning 7120/783
Observing that the region between 7120/770 is critical for maximal activation of the human SPARC promoter in c-Jun/MCF7 cells we sought to identify DNA binding complexes which specifically bind to this region. Incubation with MCF7 and c-Jun/MCF7 nuclear extracts resulted in the formation of multiple complexes binding to a DNA probe spanning 7120/ 783 (Figure 10b ). Competition analysis using an SP-1 consensus oligonucleotide resulted in specific inhibition of complex 1 and complex 3, whereas incubation with a SP-1 mutant probe had no effect on these complexes. These results suggest that SP family proteins may be a part of these complexes. However, supershift analysis with an SP-1 antibody failed to result in a significant inhibition of binding or supershift under these conditions (data not shown).
Activation of the SPARC promoter by SP1 and SP3
In order to determine if SP1 or SP3 play a role in SPARC promoter activation through the 50 base pair c-Jun responsive element (7120 to 770) we assayed the activity of two SPARC promoter deletion plasmids in response to increasing amounts of SP1 or SP3 in Drosophila SL2 cells. Drosophila SL2 cells are devoid of endogenous SP family proteins which allows us to examine the effect of exogenous SP family proteins on promoter activity. In Figure 11 we demonstrate that the 7120-+28 promoter fragment, but not the 770-+28 promoter fragment is responsive in a dose dependent manner to the addition of either SP1 ( Figure  11a ) or SP3 (Figure 11b ). These results provide further evidence that SP family proteins may be involved in cJun mediated SPARC promoter activation.
In conclusion, we have identified two complexes exhibiting SP-1 'like' binding specificity bound to an area essential for maximal SPARC promoter activation in response to c-Jun. The result of this promoter activation is a dramatic increase in SPARC RNA and protein. This increase in SPARC expression results in a concomitant increase in the motility and invasive behavior of c-Jun/MCF7 cells. We are able to significantly revert these phenotypic changes by inhibiting SPARC expression indicating a requirement for SPARC in the progression of MCF7 cells to an invasive phenotype in response to the proto-oncogene c-Jun.
Discussion
The transcription factor, c-Jun, is capable of initiating alterations in cellular gene expression profiles resulting in a variety of phenotypic changes including the enhancement of motility and invasion Rinehart-Kim et al., 2000; Smith et al., 1999) . These phenotypic characteristics are a hallmark of tumor progression in which cells must break away from the primary tumor, extravasate and recolonize in a new location. Our previous studies have revealed Kim et al., 2000) . One of these gene targets encodes the SPARC protein (Rinehart- Kim et al., 2000) . In this study we have taken the next step in determining the significance of SPARC induction by c-Jun as it relates to two phenotypic behaviors: motility and invasion. We demonstrate that SPARC expression is required but not sufficient to induce these phenotypic changes (Figures 2 and 3 ). In addition, we demonstrate that our MCF7 cell model represents transcriptionally 'active' and 'inactive' states with respect to SPARC gene transcription. The trigger in this model is stable overexpression of the c-Jun proto-oncogene. We have mapped the c-Jun responsive element to a 50 base pair region devoid of any AP-1 or AP-1 like sites but responsive to both SP1 and SP3. These results suggest an indirect mechanism for the regulation of SPARC by c-Jun possibly through the activation of SP1 and/or SP3. Because these studies were performed in vitro using a promoter fragment out of its genomic context, our results do not rule out the possible involvement of direct AP-1 interaction with other regions within the SPARC gene locus. Interestingly, examination of the extended SPARC gene on chromosome 5 revealed six upstream consensus AP-1 sites and four downstream intronic AP-1 recognition elements. Each of these sites is in a suitable context for high affinity binding of cJun containing complexes from nuclear extracts derived from our c-Jun/MCF7 cell lines (Bos-unpublished-data not shown). Our Northern and RT -PCR results (Figures 1 and 4) demonstrate that MCF7 cells are completely devoid of SPARC RNA suggesting active suppression of the gene locus. It is possible that direct binding of c-Jun complexes to one or more of these AP-1 elements stimulates recruitment of histone acetylases resulting in chromatin remodeling and open access to promoter elements. This possibility is interesting because in Figure 10 , complexes 1 and 3, which exhibit SP-1 like binding specificity, are present in both MCF7 and MCF7/c-Jun nuclear extracts. The capacity of similar complexes from each cell line to bind in vitro may not accurately reflect their ability to do so in vivo, again, due to effects of chromatin remodeling. Another possibility is that these factors may bind in an inactive or repressive state in MCF7 cells, but undergo activation or reorganization in response to c-Jun overexpression. The consequence of such a scenario may be activation or repression Figure 6 Gel shift competition analysis showing that AP-1 binding to the non-canonical AP-1 site at 71051/71045 is specific. AP-1 binding from c-Jun/MCF7 nuclear extracts to a radiolabeled DNA probe (50 000 c.p.m.) containing the non-canonical AP-1 site at 71051/71045 where (7) represents no competitor followed by increasing amounts of the indicated AP-1 consensus or unrelated competitors (2.5, 5, 10, 25 and 50X molar excess) Relative luciferase values were normalized to protein concentration depending on the SP family members present in the complex. For example, the SP family protein SP-3 has been shown to be a bifunctional transcriptional regulator capable of recognizing SP-1 binding sites and repressing transcription depending on the promoter and cellular context (Majello et al., 1997) . Testing of this hypothesis will require a more detailed analysis of the mechanisms involved in SPARC gene regulation.
A growing number of studies have revealed an association between SPARC expression and invasive behavior in a variety of tumors. Exogenously expressed SPARC has been shown to enhance the invasive capacity of both breast and prostate cell lines (Gilles et al., 1998; Jacob et al., 1999; Thomas et al., 2000) .
In addition, immunohistochemical studies on clinical breast cancer specimens have revealed an association of SPARC expression with malignancy (Bellahcene and Castronovo, 1995; Porter et al., 1995) as well as an inverse relationship with estrogen receptor alpha expression (Graham et al., 1997) . Consistent with our studies presented here, examination of 13 breast cancer cell lines revealed that SPARC was highly expressed in three of the four highly invasive cell lines and not expressed in the 9 weakly invasive lines (Zajchowski et al., 2001) . One conflicting report, using immunohistochemical staining, concluded that there was no relationship between SPARC expression and estrogen receptor status or any other clinicopathological properties (Kim et al., 1998) . Resolution of these discrepancies will require additional studies.
One of the possible mechanisms by which SPARC may contribute to motility and invasion is through matrix metalloprotease (MMP) activation. In vitro, SPARC has been shown to activate MMP2 in two invasive breast tumor cell lines, MDA-MB-231 and BT549 (Gilles et al., 1998) . The balance of active MMPs and tissue inhibitors of metalloproteinases (TIMPs) on the cell surface is known to contribute to the invasive capacity of tumor cells (Jiang et al., 2002) . Therefore, upregulation of SPARC, whether by surrounding stromal cells or by the tumors themselves, can tilt the balance at the cell surface to favor extracellular matrix degradation and subsequent tumor invasion. This may explain why SPARC is not sufficient to induce invasion of MCF7 cells that lack MT1-MMP (Gilles et al., 1998 ).
An interesting dichotomy exists with respect to SPARC regulation by c-Jun. In rat and chick embryo fibroblasts, c-Jun expression downregulates SPARC (Kraemer et al., 1999; Mettouchi et al., 1994; . This downregulation is required for fibrosarcoma development (Colombo et al., 1991; . In contrast, in our MCF7 model, c-Jun highly upregulates SPARC ( (Rinehart-Kim et al., 2000) , and Figures 1 and 4) and this upregulation plays an important role in tumor cell invasion in vitro (Figure 3) . In each of these models, the c-Jun responsive region maps to the same general GGA/GC rich region suggesting indirect regulation by AP-1.
This dichotomy of SPARC behavior also exists in human tumors. For example, SPARC upregulation is associated with invasive behavior of breast, prostate and colorectal carcinomas as well as invasive meningioma and melanoma (Bellahcene and Castronovo, 1995; Graham et al., 1997; Jacob et al., 1999; Kato et al., 2000; Ledda et al., 1997a; Porte et al., 1995; Porter et al., 1995; Sturm et al., 2002; Thomas et al., 2000) . In contrast, ovarian carcinoma and fibrosarcoma development exhibit an inverse correlation with SPARC expression Colombo et al., 1991; Mok et al., 1996; Yiu et al., 2001 ) perhaps related to increased apoptotic activity (Yiu et al., 2001) .
A common underlying theme prevails in which SPARC is at the center of a network of phenotypic changes resulting in progression of tumor cells. Depending on the tumor type, SPARC expression can be an asset or a liability. In either case, it may serve as an important tumor biomarker related to tumor cell progression as well as a potential therapeutic target. c-Jun appears to regulate SPARC in both a positive and negative manner depending on the cell type. It will be interesting to dissect the molecular mechanisms behind this differential regulation.
Materials and methods
Cloning of the human SPARC coding region
Total RNA was isolated from c-Jun/MCF7 cells using Trizol reagent (Life Technologies, Rockville, MD, USA) according to manufacturer's recommendations. One hundred ng of total RNA was reverse transcribed using Moloney Murine Leukemia Virus reverse transcriptase (Promega Corp., Madison, WI, USA) and random hexamers. The human SPARC coding region was amplified from this cDNA mix by using Advantage HF-2 PCR kit (Clontech Laboratories, Palo Alto, CA, USA) containing Taq polymerase and a proofreading enzyme using the following primers: SPARC cloning primer 1 5'gtcagaagcttatgagggcctggatcttctttctcc3', SPARC cloning primer 2 5'gtcagatcgattggatttagatcacaagatccttgtcg3'. SPARC cloning primer 1 has a HindIII site incorporated at the 5' end to facilitate subsequent cloning while SPARC cloning primer 2 has a ClaI site at its 5' end. Thermocycling conditions for SPARC amplification are as follows: step 1, 958C for 2 min, step 2 958C for 30 s, step 3 688C for 30 s, step 4 688C for 1 min, repeat steps 2 -4 29 times. The resultant PCR product is expected to be 944 base pairs consisting of 912 bases corresponding to the human SPARC coding region. PCR products were loaded on 1% low melting point agarose/1X TBE gel stained with Gelstar reagent at a final concentration of 1X for visualization. The SPARC amplicon was purified using the Qiaquick gel extraction kit (Qiagen Corp., Valencia, CA, USA) following manufacturer's recommendations. This purified RT -PCR product was digested with HindIII and ClaI restriction enzymes and ligated to a similarly digested pGEM-7Zf+ plasmid (Promega Corp., Madison, WI, USA). Following transformation into DH5a E. coli competent cells, a positive clone was screened and selected for sequence verification of the SPARC coding region insert. DNA sequencing was conducted using an ALF automated DNA sequencer (Amersham/Pharmacia). Primers and sequence comparisons are based on Genbank accession number NM_003118 corresponding to the human SPARC mRNA.
Generation of SPARC/MCF7 and JunD/MCF7 stable cell lines SPARC/MCF7 and JunD/MCF7 stable cell lines were made utilizing the pLPCX retroviral vector system (Clontech Laboratories, Palo Alto, CA, USA) according to manufacturer's recommendations. Briefly, the human SPARC coding region was subcloned from the pGEM7Zf+ HindIII/ClaI site into the HindIII/ClaI site of pLPCX retroviral vector (Clontech Laboratories, Palo Alto, CA, USA). The rat JunD coding region (kind gift from Dr Rodrigo Bravo) was subcloned from HindIII/NotI into a HindIII/NotI digested LPCX vector. Colonies were screened and a positive clone selected. Purified plasmid DNA containing the appropriate expression cassettes for SPARC and JunD were transfected into the RetroPack PT67 packaging cell line in order to produce infectious retrovirus. Transfections were conducted using Fugene reagent (Roche Diagnostics Corp., Indianapolis, IN, USA) according to manufacturer's recommendations. After 48 h PT67 cells were placed under antibiotic selection using 2.5 mg/ml of puromycin (Clontech Laboratories, Palo Alto, CA, USA). Positive clones were allowed to grow together until confluent. Growth media containing virus was harvested and filtered through a 0.45 mm cellulose acetate filter for subsequent infection into target cells. Target cell infection was conducted by incubating MCF7 cells in the presence of viral supernatant and 10 mg/ml of polybrene. Cells were incubated with virus for 6 h then refed with Improved MEM-zinc option (Mediatech Inc., Herndon, VA, USA) containing 10% FBS and 1% penicillin/streptomycin. Forty-eight hours after infection cells were placed under antibiotic selection using 2.0 mg/ml of puromycin (Clontech Laboratories, Palo Alto, CA, USA) for MCF7 cells. Individual antibiotic resistant colonies were selected and screened for the presence of SPARC and exogenous JunD transcript expression as well as SPARC and JunD protein expression.
Northern blot analysis
Northern blot analysis was performed as previously described (Hadman et al., 1996) . The SPARC probe was previously described (Rinehart- Kim et al., 2000) .
Western blot analysis
Protein was isolated from total cell lysates by a series of freezing and thawing. Protein was quantitated using the Bradford method. Fifty mg of each sample were loaded on a 10% polyacrylamide gel for separation of proteins. Following transfer to a nitrocellulose membrane, the samples were incubated with a mouse monoclonal primary antibody (OST1) specific for SPARC (Biodesign International, Saco, ME, USA). Following a series of washes, samples were incubated with anti-mouse HRP conjugated secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Protein was visualized by enhanced chemiluminescence (Amersham Biosciences, Piscataway, NJ, USA) and exposure to film. Protein size was estimated using Rainbow marker as the standard (Amersham Biosciences, Piscataway, NJ, USA).
Construction of anti-sense SPARC adenovirus
Replication incompetent adenoviruses were constructed using the Adeno-X Expression System (Clontech Laboratories, Palo Alto, CA, USA) according to manufacturer's recommendations. Briefly, the human SPARC coding region was subcloned from the HindIII/XhoI sites of PGEM7Zf+ and inserted into the HindIII/XhoI sites of the vector pcDNA3.1/ Zeo. pcDNA3.1/Zeo/SPARC was subsequently digested with AflII/ApaI restriction enzymes to subclone the SPARC coding region in the anti-sense orientation into an AflII/ ApaI digested pShuttle vector (Clontech Laboratories, Palo Alto, CA, USA). pShuttle/SPARC and pShuttle/LacZ control vectors were digested with I-Ceu-I/PI-SceI in order to ligate into similarly cut Adeno-X (Clontech Laboratories, Palo Alto, CA, USA) genomes resulting in adenovirus-SPARC anti-sense and adenovirus-LacZ viral genomic DNA. Following digestion using SwaI restriction enzyme, adenovirus-SPARC anti-sense and adenovirus-LacZ plasmids were transformed into DH5a competent E. coli. Subsequently, adenoviral plasmid DNA was purified using the NucleoBond Plasmid Maxi Kit (Clontech Laboratories, Palo Alto, CA, USA) according to manufacturer's instructions. Purified plasmid DNA was digested with PacI restriction enzyme prior to transfection into HEK293 packaging cell line. Cells were transfected with purified plasmid DNA using Fugene (Roche Diagnostics Corp., Indianapolis, IN, USA) reagent according to manufacturer's recommendations. Cells were harvested when cytopathic effect (CPE) was evident throughout the plate. These cells were then pelleted and resuspended in phosphate buffered saline. Virus was freed from cells by vortexing and a series of freeze/thaw cycles. This supernatant containing virus was used to re-infect HEK293 cells in order to increase the viral titer. Following a single round of viral amplification, viral titer was determined using plaque assay according to manufacturer's recommendations. In order to determine the optimal multiplicity of infection (MOI) for cJun/MCF7 cells, a series of infections were conducted over a broad range of MOI's using adenovirus-LacZ as a means of determining the number of infected cells following staining for b-galactosidase activity. An optimal MOI of between 5 -10 was determined to infect the majority of cells without being cytotoxic. This MOI was used to infect c-Jun/MCF7 cells with adenovirus-SPARC anti-sense in order to suppress endogenous SPARC expression. A time course following infection was conducted in order to determine the optimal time following infection in which endogenous SPARC expression was suppressed to the greatest extent. These conditions were used for all subsequent experiments.
Motility and invasion assays
Motility and invasion assays were performed as previously described . Briefly, assays were performed in a Neuro probe 48-well chemotaxis chamber using a PVP-Free polycarbonate membrane with 8.0 mm pores coated with 0.1 mg/ml gelatin (motility) or 0.04 mg/ml collagen IV followed by an even layer of 1 mg/ml matrigel (500 ml per membrane) (invasion). NIH3T3 conditioned media was placed in the lower chamber and 100 000 cells were loaded in the upper chamber. Chambers were incubated in a tissue culture incubator at 378C, 5% CO 2 for 4 -5 h. The membranes were then stained (Diff-Quik) and cells on the upper surface were removed by scraping. Migration and invasion was quantitated by counting cells on the lower surface from a minimum of three representative high power (400X) fields.
Promoter-reporter constructions
The SPARC promoter constructs corresponding to nucleotides 71409/+28 and 7120/+28 in pGL2-Basic (Promega Corp., Madison, WI, USA) were described previously . To generate the SPARC promoter 5' deletion construct corresponding to positions 770/+28 we used polymerase chain reaction (PCR) to amplify this region from the SPARC promoter 71409/+28-pGL2-Basic parental vector. The following primers were used: primer 1 (XhoI)770/746 5'atgagctcgagacggggtggaggggagatgacccag3', primer 2 pGL2-Basic primer 5'ctttatgtttttggcgtcttcca3'. Two ng of plasmid was used as a template and mixed with the following PCR master mix components: 4 ml dNTPs (2.5 mM each), 10X Advantage2-HF reaction buffer (Clontech Laboratories, Palo Alto, CA, USA), 150 ng of each primer, 0.5 ml Advantage2-HF enzyme mix containing Taq polymerase and a Pfu polymerase (Clontech Laboratories, Palo Alto, CA, USA). Thermocycling conditions were as follows: step 1 958C for 2 min, step 2 958C for 30 s, step 3 658C for 30 s, step 4 688C for 30 s, repeat steps 2 -4 for a total of 25 cycles. PCR products were loaded on a 1% low melt agarose gel and visualized by staining with ethidium bromide and gel purified using the Qiaquick gel extraction kit (Qiagen Corp., Valencia, CA, USA). The purified product was digested with XhoI and HindIII restriction enzymes and subsequently ligated into a similarly digested pGL2-Basic vector resulting in SPARC promoter 770/+28-pGL2-Basic. Two-step PCR (Basso et al., 2000) was used to generate point mutations within the SPARC promoter AP-1 'like' site at 71051/71045. The pGL2-Basic forward primer 5'tgtatcttatggtactgtaactg3' designated (A1) corresponds to a region of the pGL2-Basic vector which is upstream of the vectors SmaI site. The pGL2-Basic reverse primer 5'ctttatgtttttggcgtcttcca3' designated (B1) corresponds to a region immediately downstream of the vector HindIII site. The internal primers used to introduce point mutations to the AP-1 'like' are as follows: Mutated to consensus: Primer (C1) forward 5'gcctgggcgacagagtgagtcag3'; Primer (D1) reverse 5'gttttgagacagagtctgactcactc3'; Triple mutant: Primer (E1) forward 5'gcctgggcgacagagcgaatgag3'; Primer (F1) reverse 5'gttttgagacagagtctcattcgctc3'. PCR was performed using the following primer combinations using the same PCR reaction master mix and amplification conditions A1/D1, A1/F1, B1/C1, B1/E1. The PCR master mix contained the following: 4 ml dNTPs (2.5 mM each), 10X Advantage2-HF reaction buffer (Clontech Laboratories, Palo Alto, CA, USA), 150 ng of each primer, 0.5 ml Advantage2-HF enzyme mix containing Taq polymerase and a Pfu polymerase (Clontech Laboratories, Palo Alto, CA, USA). Thermocycling conditions were as follows: step 1 958C for 2 min, step 2 958C for 30 s, step 3 638C for 30 s, step 4 688C for 60 s, repeat steps 2 -4 for a total of 25 cycles. Products were purified on a 1% low-melt agarose gel and gel purified using the Qiaquick gel extraction kit (Qiagen Corp., Valencia, CA, USA). A portion of the purified PCR products containing the corresponding mutations were mixed into a second PCR reaction to produce the full-length mutated product. PCR products generated with the following primer combinations were mixed and used as the template for subsequent PCR reactions: A1/D1 and B1/C1 containing the mutation to a consensus context, A1/F1 and B1/E1 containing the mutations to a more mutated context. Amplification of full-length mutant promoter fragments was done as described above except that step 4 was extended for 1 min 30 s. These full-length mutated PCR products were gel purified using the Qiaquick gel extraction kit (Qiagen Corp., Valencia, CA, USA). Purified amplicons were treated with DNA polymerase I large (Klenow) fragment followed by digestion with HindIII restriction enzyme. The mutant promoter fragments were subsequently cloned into a SmaI/ HindIII digested pGL2-Basic vector.
Luciferase assays
Cells were plated in 6 well plates at a density of 3610 5 cells/ well approximately 24 h prior to transfection. Three mg of plasmid DNA was added to 6 ml of Fugene (Roche Diagnostics Corp., Indianapolis, IN, USA) reagent pre-mixed with serum-free IMEM and added dropwise to each well. After 48 h, cells were washed twice with 16 phosphate buffered saline (PBS). Following the final PBS wash 150 ml of Reporter Lysis Buffer (Promega Corp., Madison, WI, USA) was added to cells and incubated for 10 min. These samples were frozen at 7808C for at least 1 h and collected for analysis. Luciferase assays were done following manufacturer's recommendations and quantitated using a luminometer (Turner Designs, Inc., Sunnyvale, CA, USA) with the following parameters: delay=2 s, integration=15 s, replicates=3. Relative luciferase values were normalized to protein concentration per volume assayed. Protein quantitation was conducted using the Bradford method.
Gel shifts and supershifts and competitions
MCF7, c-Jun/MCF7 and JunD/MCF7 nuclear extracts were prepared as described previously (Hadman et al., 1993) . P 32 labeled gel shift probes were prepared and AP-1 gel shift reactions conducted as described previously (Rinehart- Kim et al., 2000) with amount of probe used in individual experiments expressed as counts per minute (c.p.m.) as indicated. AP-1 DNA binding competitors were generated in the same way as P 32 labeled probes except that cold dATP was used in the labeling reaction. Cold competitors were added in the indicated amounts for 20 min prior to incubation with the appropriate P 32 labeled probe. Gel shifts using antibodies to either compete or supershift DNA bound proteins were done by pre-incubating the nuclear extracts for 20 min with 2 mg of anti c-Jun antibody directed against the DNA binding domain (Santa Cruz Biotechnology, Santa Cruz, CA, USA), 2 mg of anti Fra-1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or 2 mg of anti p107 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
To analyse DNA binding of protein complexes with SP family binding specificity the gel shift reactions were done as indicated above with the following modifications. Reactions were electrophoresed on a 5% non-denaturing polyacrylamide gel in 0.5% TBE running buffer at room temperature. SP-1 consensus and mutant competitors were added to nuclear extracts and DNA binding buffer 20 min prior to incubation with the indicated probe. The binding buffer used was as follows: 20 mM HEPES, 35% glycerol, 0.2 mM EDTA, 40 mM NaCl, 8 mM MgCl 2 , 5 mM DTT, 4 mM Spermidine and 0.1% NP-40. 
RNA isolation
Total cellular RNA was isolated using Trizol reagent (Life Technologies, Rockville, MD, USA) according to the manufacturer's protocol.
cDNA synthesis
One hundred ng of total RNA was incubated in the presence of 20 pmol of random hexamers (Perkin-Elmer) at 708C for 2 min followed by snap-cooling at 48C. The reverse transcription master mix was then added to the RNA/primer mixture. The RT master mix consisted of 5 ml of a 56 Moloney Murine Leukemia Virus Reverse Transcriptase (MMLV-RT) reaction buffer (Promega Corp., Madison, WI, USA), 20 units of recombinant Rnasin (Promega Corp., Madison, WI, USA), 4 ml of dNTP mix (2.5 mM each), 200 units of MMLV reverse transcriptase (Promega Corp., Madison, WI, USA) and nuclease-free water (Promega Corp., Madison, WI, USA). The reverse transcription reaction was then incubated at 428C for 1 h followed by heating at 948C for 5 min to halt cDNA synthesis. The samples were then cooled to 48C.
Semi-quantitative reverse transcriptase polymerase chain reaction (RT -PCR)
18S ribosomal subunit A 1.5 ml aliquot of the RT reaction was used to amplify a portion of the 18S ribosomal subunit using gene specific primers. 18S ribosomal subunit sense primer: 5'tgactctagataacctcggg3'. 18S ribosomal subunit antisense primer: 5'cccaagatccaactacgagc3'. The PCR reaction mixture consisted of the following: 1.5 ml of template cDNA, 5 ml of 10X PCR buffer (Clontech Laboratories, Palo Alto, CA, USA), 4 ml dNTP mix (2.5 mM each), 150 ng of sense and anti-sense 18S primers, 0.5 ml of a 50X stock of Titanium Taq DNA polymerase (Clontech Laboratories, Palo Alto, CA, USA) and nuclease free water for a 50 ml total reaction volume. Polymerase chain reaction for 18S was conducted using a Biometra T-Gradient Thermocycler (Biometra Inc., Tampa, FL, USA) as follows: step one=958C for 1 min, step two=958C for 30 s, step three=558C for 30 s, step four=688C for 45 s. Steps 2 -4 were repeated for a total of 13 cycles which corresponded to mid-log phase amplification using 100 ng of input, total cellular RNA. The expected amplification product is 403 base pairs.
SPARC A 2 ml aliquot of the RT reaction was used to amplify a portion of SPARC utilizing a gene specific primer pair that would span intronic regions. SPARC sense primer: 5'gtcagaagcttatgagggcctggatcttctttctcc3'. SPARC anti-sense primer: 5'gtcagatcgattggatttagatcacaagatccttgtcg3'. The PCR reaction mixture consisted of the following: 2 ml of template cDNA, 5 ml of 10X PCR buffer (Clontech Laboratories, Palo Alto, CA, USA), 4 ml dNTP mix (2.5 mM each), 150 ng of sense and anti-sense SPARC primers, 0.5 ml of a 50X stock of Titanium Taq DNA polymerase (Clontech Laboratories, Palo Alto, CA, USA) and nuclease free water for a 50 ml total reaction volume. Polymerase chain reaction for SPARC was conducted using a Biometra T-Gradient Thermocycler as follows: step one=958C for 1 min, step two=958C for 30 s, step 3=688C for 30 s, step 4=688C for 1 min. Steps 2 -4 were repeated for a total of 30 cycles which corresponded to mid-log phase amplification using 100 ng of input, total cellular RNA. The expected amplicon size is 944 base pairs.
Visualization of PCR amplicons RT -PCR products were electrophoresed on a 1.5% agarose gel stained with Gelstar reagent (Biowhittaker Molecular Applications, Inc.). Following UV transillumination at 312 nM, images were captured using a Kodak DC40 digital camera equipped with an ethidium bromide lens filter and PCR amplicon signals quantitated using Kodak 1D Image Analysis software package.
18S and SPARC log-phase quantitation In order to utilize 18S as an endogenous control for standardization purposes it was necessary to identify when 18S amplification was in midlog phase to allow for appropriate quantitation. This was done by conducting multiple, parallel 18S PCR reactions over a range of cycle numbers and input RNA concentrations utilizing aliquots from the same cDNA mixtures as the template. For SPARC, mid-log phase amplification was conducted by testing samples over a range of different cycle numbers and varying input RNA concentration as well. Following quantitation using Kodak 1D Image Analysis software, the values were plotted as relative intensity vs cycle number as well as relative intensity vs input RNA amount.
The cycle number which correlated to mid-log phase amplification using 100 ng of input total RNA was used for all subsequent experiments for standardization of SPARC expression between the two cell types. Input RNA was adjusted to 10-fold higher (1.0 mg) and 10-fold lower (10 ng) in the reverse transcription reaction to insure linear amplification over a one-log change in RNA concentration in either direction.
Transient transfections in Drosophila SL2 cells SL2 Drosophila cells (Schneider, 1972) were routinely grown in Schneider's Drosophila medium (Invitrogen) supplemented with 10% fetal calf serum and antibiotics at 258C in air. For transfection, cells were seeded at a density of 2610 6 in 2 ml in a 35 mm-diameter dish and transfected 18 to 20 h later using a standard protocol for calcium phosphate-mediated transfection for adherent cells (Sambrook et al., 1989) with HEPES-buffered saline adjusted to pH 7.0. Cells were gently washed and incubated in fresh medium the next morning. Cell lysates were prepared 48 h after transfection, total protein quantitated and luciferase activity was measured.
Typically, a transfection experiment included 5 mg of reporter plasmid per petri dish and various amounts of pAC expression vectors normalized to 2 mg with the empty pAC vector. The human SPARC promoter fragments were cloned in the pGL2 plasmid (Promega) in front of the reporter luciferase gene. Plasmids carrying the promoter fragments 1409/+28 and 120/+28 were described previously . pAC Drosophila expression vectors for Sp1 and Sp3 were previously described (Courey and Tjian, 1988; Dennig et al., 1996) . The relative luciferase activity represents the ratio SPARC-luciferase/pGL2-luciferase with each point corresponding to the average value of three independently transfected dishes in the same experiment.
